Skip to main content
Clinical Trials/CTRI/2009/091/000056
CTRI/2009/091/000056
Completed
Phase 3

A comparative clinical trial for the evaluation of the efficacy and safety of FDC of Lornoxicam (4 mg) and Paracetamol (500 mg)with Lornoxicam (4 mg) alone for short term treatment of mild to moderate pain associated with extra articular inflammation

Aristo Pharmaceuticals pvt ltd Mumbai0 sites201 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Aristo Pharmaceuticals pvt ltd Mumbai
Enrollment
201
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Aristo Pharmaceuticals pvt ltd Mumbai

Eligibility Criteria

Inclusion Criteria

  • Patients with either sex, from 18\-60 years age. Informed consent, extra articular inflammation.

Exclusion Criteria

  • Female pregnant or with chances of pregnancy or nursing, History of allergy or hypersensitivity. physical/clinical abnormalities, any condition which affect study of drug.

Outcomes

Primary Outcomes

Not specified

Similar Trials